NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free ACHV Stock Alerts $4.90 -0.19 (-3.73%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$4.80▼$5.0750-Day Range$4.35▼$5.5052-Week Range$3.03▼$6.25Volume309,837 shsAverage Volume130,939 shsMarket Capitalization$168.27 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Achieve Life Sciences alerts: Email Address Achieve Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside185.7% Upside$14.00 Price TargetShort InterestBearish2.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.20 out of 5 starsMedical Sector764th out of 915 stocksDiagnostic Substances Industry12th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAchieve Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Achieve Life Sciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.77% of the outstanding shares of Achieve Life Sciences have been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 26.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHV. Previous Next 2.4 News and Social Media Coverage News SentimentAchieve Life Sciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows3 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 33.52% of the stock of Achieve Life Sciences is held by institutions.Read more about Achieve Life Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.04) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Achieve Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About Achieve Life Sciences Stock (NASDAQ:ACHV)Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Read More ACHV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACHV Stock News HeadlinesMay 29, 2024 | finance.yahoo.comAchieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-CigarettesMay 25, 2024 | finance.yahoo.comAchieve Life Sciences, Inc. (ACHV)May 17, 2024 | globenewswire.comAchieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual MeetingMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Achieve Life Sciences Amid Positive Drug Development Progress and Strong Financial PositionMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Achieve Life Sciences on Strong Clinical Progress and Solid Financial FootingMay 10, 2024 | finance.yahoo.comAchieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAchieve Life Sciences Inc (ACHV) Reports Q1 2024 Financial ResultsMay 9, 2024 | globenewswire.comAchieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 9, 2024 | usnews.comIsraeli Defence Minister Tells 'Friends and Enemies' Israel Will Achieve War AimsMay 6, 2024 | globenewswire.comAchieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal MedicineApril 28, 2024 | latimes.comWomen Are on Track to Achieve Parity in Gender Representation Among Corporate Leadership Roles as Soon as 2030April 26, 2024 | msn.comAchieve Life Sciences files to sell 13.09M shares of common stock for holdersApril 25, 2024 | globenewswire.comAchieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024April 18, 2024 | nasdaq.comJonesTrading Initiates Coverage of Achieve Life Sciences (ACHV) with Buy RecommendationApril 17, 2024 | finance.yahoo.comAchieve Institute CEO Mark Cunningham Named to the Forbes Business CouncilApril 13, 2024 | msn.comMcNair rolls past College Achieve Paterson - Softball recapApril 11, 2024 | finance.yahoo.comAchieve Life Sciences to Present at Life Science Innovation Northwest 2024 ConferenceApril 4, 2024 | seekingalpha.comAchieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x ReturnsApril 1, 2024 | finance.yahoo.comACHV: 2023 ResultsMarch 30, 2024 | seekingalpha.comAchieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Achieve Life Sciences Inc Earnings CallMarch 28, 2024 | benzinga.comRecap: Achieve Life Sciences Q4 EarningsMarch 28, 2024 | finance.yahoo.comAchieve Life Sciences Inc Reports Year-End Loss, Progresses Towards FDA ApprovalMarch 28, 2024 | globenewswire.comAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate UpdateMarch 28, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 28, 2024See More Headlines Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHV CUSIP68230A10 CIK949858 Webachievelifesciences.com Phone(604) 210-2217Fax425-686-1600Employees22Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+185.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-176.97% Return on Assets-76.60% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio3.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-70.00Miscellaneous Outstanding Shares34,341,000Free Float33,654,000Market Cap$168.27 million OptionableOptionable Beta1.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Richard A. B. Stewart (Age 65)Executive Chairman Comp: $663.75kMr. John A. Bencich M.B.A. (Age 47)CEO & Director Comp: $781.75kDr. Cindy Jacobs M.D. (Age 66)Ph.D., President, Chief Medical Officer & Director Comp: $652.74kMr. Jerry Wan (Age 42)Principal Accounting Officer Dr. Anthony Clarke Ph.D. (Age 68)Chief Scientific Officer Comp: $546kMs. Jaime XinosExecutive Vice President of CommercialMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXAgenusNASDAQ:AGENVanda PharmaceuticalsNASDAQ:VNDAEmergent BioSolutionsNYSE:EBSXOMANASDAQ:XOMAView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 12,930 shares on 5/20/2024Ownership: 0.038%Propel Bio Management LLCBought 2,453,092 shares on 5/14/2024Ownership: 7.144%Vanguard Group Inc.Bought 342,731 shares on 5/10/2024Ownership: 2.769%CVI Holdings LLCBought 567,192 shares on 5/7/2024Ownership: 1.656%View All Institutional Transactions ACHV Stock Analysis - Frequently Asked Questions Should I buy or sell Achieve Life Sciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACHV shares. View ACHV analyst ratings or view top-rated stocks. What is Achieve Life Sciences' stock price target for 2024? 3 brokers have issued 12 month price objectives for Achieve Life Sciences' shares. Their ACHV share price targets range from $11.00 to $20.00. On average, they predict the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts. How have ACHV shares performed in 2024? Achieve Life Sciences' stock was trading at $4.12 at the beginning of the year. Since then, ACHV shares have increased by 18.9% and is now trading at $4.90. View the best growth stocks for 2024 here. Are investors shorting Achieve Life Sciences? Achieve Life Sciences saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 949,700 shares, an increase of 26.5% from the May 15th total of 750,500 shares. Based on an average trading volume of 116,100 shares, the short-interest ratio is currently 8.2 days. View Achieve Life Sciences' Short Interest. When is Achieve Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ACHV earnings forecast. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. What ETF holds Achieve Life Sciences' stock? Simplify Propel Opportunities ETF holds 217,845 shares of ACHV stock, representing 1.15% of its portfolio. When did Achieve Life Sciences' stock split? Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI). Who are Achieve Life Sciences' major shareholders? Achieve Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Propel Bio Management LLC (7.14%), Vanguard Group Inc. (2.77%), CVI Holdings LLC (1.66%), Virtu Financial LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACHV) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.